EGFR dimer disruptors and use of the same

A compound, or pharmaceutically acceptable salt thereof, having the structure of Formula I:

• wherein
• X is S—C0-6alkylene, and said alkylene is optionally substituted with 1-3 groups independently selected from halo, N(R3)2, and OR3;
• Y is null;
• A is C6-10 aryl optionally substituted with 1 to 3 R4;
• B is 5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S, and said heteroaryl is optionally substituted with 1 to 3 R5;
• R1 and R2 together with the carbon atom to which they are attached form a 6 membered heterocycloalkyl ring, wherein the heterocycloalkyl ring has 1 or 2 ring heteroatoms selected from O, S, and N, and wherein said cycloalkyl ring or heterocycloalkyl ring is optionally substituted with 1-2 R6;
• each R3 is independently H or C1-6 alkyl;
• each R4 and R5 is independently C1-6 alkyl, C1-6 haloalkyl, halo, or C1-6 alkoxy;
• and
• R6 is C1-6 alkyl, C1-6 haloalkyl, (C═O)R3, (C═O)OR3, CON(R3)2, C0-3alkylene-C3-8cycloalkyl, C0-3alkylene-C6-10aryl, or C0-3alkylene-(5-10 membered heteroaryl having 1-4 heteroatoms selected from N, O, and S), wherein the aryl or heteroaryl is optionally substituted with 1 to 3 R5.